Ginkgo biloba

  • Timothy S. Tracy
Part of the Forensic Science and Medicine book series (FSM)


Controlled studies suggest that administration of Ginkgo biloba (GB) extract has limited effectiveness in improving memory and cognition, either in elderly subjects with dementia or healthy subjects. GB administration does seem to reverse sudden hearing loss in patients with mild cases of this disorder. Additionally, GB administration may blunt the rise in blood pressure in response to stress and may blunt the glycemie response after an oral glucose tolerance test. Despite the lack of evidence of effects on coagulation in vivo, a number of case reports of excessive bleeding in patients taking GB have been reported. Finally, GB does not appear to be prone to causing drug interactions, except for agents metabolized by cytochrome P450 2C19 (in which case, induction is observed).

Key Words

Ginkgolides dementia memory diabetes bleeding disorders 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tyler VE, ed. The Honest Herbal, 3rd edition. Binghamton: Pharmaceutical Products Press, 1993.Google Scholar
  2. 2.
    Anonymous. Ginkgo. In: The Review of Natural Products. St. Louis: Facts and Comparisons, 1998.Google Scholar
  3. 3.
    Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of peripheral type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo Biloba extract EGb 761 and isolated ginkgolides. Endocrinology 1996;137:5707–5718.PubMedCrossRefGoogle Scholar
  4. 4.
    Hasenohrl RU, Nichau CH, Frisch CH, et al. Anxiolytic-like effect of combined extracts of Zingiber officinale and Ginkgo biloba in the elevated plus-maze. Pharmacol Biochem Behav 1996;53:271–275.PubMedCrossRefGoogle Scholar
  5. 5.
    Nemecz G, Combest WL. Ginkgo biloba. US Pharm 1997;144:147–148, 151.Google Scholar
  6. 6.
    Ramassamy C, Clostre F, Christen Y, Costentin J. Prevention by a ginkgo extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol 1990;42:785–789.PubMedGoogle Scholar
  7. 7.
    Houghton P. Ginkgo. Pharm J 1994;253:122–123.Google Scholar
  8. 8.
    LeBars PL, Katz MM, Berman N, et al. A placebo controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–1332.PubMedCrossRefGoogle Scholar
  9. 9.
    Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer’s disease. Arch Neurol 1998;55:1409–1415.PubMedCrossRefGoogle Scholar
  10. 10.
    vanDongen M, vanRossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Epidemiol 2003;56:367–376.Google Scholar
  11. 11.
    vanDongen M, vanRossum E, Kessels AGH, Sielhorst HJG, Knipschild PG. The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–1194.PubMedGoogle Scholar
  12. 12.
    Mattes RD, Pawlik MK. Effects of Ginkgo biloba on alertness and chemosensory function in healthy adults. Hum Psychopharmacol Clin Exp 2004; 19:81–90.CrossRefGoogle Scholar
  13. 13.
    Mix JA, Crews WDJr. An examination of the efficacy of Ginkgo biloba extract EGb 761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med 2000;6(3):219–229.PubMedCrossRefGoogle Scholar
  14. 14.
    Allain H, Raoul P, Lieury A, LeCoz F, Gandon J. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther 1993;15:549–557.PubMedGoogle Scholar
  15. 15.
    Mix JA, Crews WD. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 ® in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol Clin Exp 2002; 17:267–277.CrossRefGoogle Scholar
  16. 16.
    Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology 2000;151:416–423.PubMedCrossRefGoogle Scholar
  17. 17.
    Hartley DE, Heinze L, Elsabagh S, File SE. Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba. Pharmacol Biochem Behav 2003;75:711–720.PubMedCrossRefGoogle Scholar
  18. 18.
    Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 ® in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.PubMedCrossRefGoogle Scholar
  19. 19.
    Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:11 36–1139.Google Scholar
  20. 20.
    Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol 2004;29:226–231.PubMedCrossRefGoogle Scholar
  21. 21.
    Issing W, Klein P, Weiser M. The homeopathic preparation Vertigoheel® versus Ginkgo biloba in the treatment of vertigo in an elderly population: a doubleblinded, randomized, controlled clinical trial. J Altern Complement Med 2005;11(l):155–160.PubMedCrossRefGoogle Scholar
  22. 22.
    Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness. Arch Intern Med 2005;165:296–301.PubMedCrossRefGoogle Scholar
  23. 23.
    Gertsch JH, Basnyat B, Johnson EW, Onopa J, Hoick PS, on behalf of the Prevention of High Altitude Illness Trial Research Group. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). Br Med J 2004;328:797–801.CrossRefGoogle Scholar
  24. 24.
    Burschka MA, Abdel-Hady Hassan H, Reineke T, vanBebber L, Caird DM, Mosges R. Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. Eur Arch Otorhinolaryngol 2001;258:213–219.PubMedCrossRefGoogle Scholar
  25. 25.
    Reisseer C, Weidauer H. Ginkgo biloba extract EGb 761 ® or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind study. Acta Otolaryngol 2001;121:579–584.CrossRefGoogle Scholar
  26. 26.
    Jung F, Mroweitz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneim Forsch 1990;40:589–593.Google Scholar
  27. 27.
    Huang SY, Jeng C, Kao SC, Yu, JJH, Liu DZ. Improved haemorrheological properties by Gingko biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 2004;23:615–621.PubMedCrossRefGoogle Scholar
  28. 28.
    Muir AH, Robb R, McLaren M, Daly F, Belch JJF. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial. Vasc Med 2002;7:265–267.PubMedCrossRefGoogle Scholar
  29. 29.
    Mehlsen J, Drabaek H, Wiinberg N, Winther K. Effects of a Gingko biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging 2002;22:375–378.PubMedCrossRefGoogle Scholar
  30. 30.
    Jezova D, Duncko R, Lassanova M, Kriska M, Moncek F. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EBg 761) in healthy volunteers. J Physiol Pharmacol 2002;53:337–348.PubMedGoogle Scholar
  31. 31.
    Chavez ML, Chavez PI. Ginkgo (Part I): History, use, and pharmacologic properties. Hosp Pharm 1998;33:658–672.Google Scholar
  32. 32.
    Sollier CBD, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haem 2003;25:251–253.CrossRefGoogle Scholar
  33. 33.
    Kohler S, Funk P, Kieser M. Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation: a randomized, placebocontrolled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis 2004; 15:303–309.PubMedCrossRefGoogle Scholar
  34. 34.
    Kim SH, Lee EK, Chang JW, Min WK, Chi HS, Kim SB. Effectsw of Ginkgo biloba on haemostatic factors and inflammation in chronic peritoneal dialysis patients. Phytother Res 2005; 19:546–548.PubMedCrossRefGoogle Scholar
  35. 35.
    Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res 2003; 108:151–160.CrossRefGoogle Scholar
  36. 36.
    Blumenthal M, ed. Ginkgo biloba. The complete German commission E monographs. Austin: American Botanical Council, 1998.Google Scholar
  37. 37.
    Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic β-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol 2000;40:647–654.PubMedCrossRefGoogle Scholar
  38. 38.
    Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic β-cell function in response to glucose loading in individuals with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 2001;41:600–611.PubMedCrossRefGoogle Scholar
  39. 39.
    Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol Clin Exp 2002; 17:279–284.CrossRefGoogle Scholar
  40. 40.
    Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol Clin Exp 2004; 19:545–548.CrossRefGoogle Scholar
  41. 41.
    Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ. Effect of ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man. Lancet 1987; 1:248–251.PubMedCrossRefGoogle Scholar
  42. 42.
    Kim YS, Pyo MK, Park PH, Hahn BS, Wu SJ, Yun-Choi HS. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba extract (EGb 761). Thrombos Res 1998;91:33–38.CrossRefGoogle Scholar
  43. 43.
    Jiang X, Williams K, Liauw W, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Brit J Clin Pharmacol 2005;59(4):425–432.CrossRefGoogle Scholar
  44. 44.
    Engelsen J, Nielsen JD, Winthere K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomized, double-blind, placebo-crossover trial. Thromb Haemost 2002;87:1075–1076.PubMedGoogle Scholar
  45. 45.
    Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.Google Scholar
  46. 46.
    vonMoltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Plant Pathol 2004;56:1039–1044.Google Scholar
  47. 47.
    He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and and CYP3A4 catalytic activities in human liver microsomes. Am J Therapeutics 2004; 11:206–212.CrossRefGoogle Scholar
  48. 48.
    Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3 A4 activity in normal volunteers. J Clin Psychopharmacol 2003;23:576–581.PubMedCrossRefGoogle Scholar
  49. 49.
    Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacokinetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14:841–850.PubMedCrossRefGoogle Scholar
  50. 50.
    Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004;44:538–542.PubMedCrossRefGoogle Scholar
  51. 51.
    Duche JC, Barre J, Guinot P, Duchier J, Cournot A, Tillement JP. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharmacol Res 1989;9:165–168.PubMedGoogle Scholar
  52. 52.
    Fourtillan JB, Brisson AM, Girault J, et al. Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 1995;50:137–144.PubMedGoogle Scholar
  53. 53.
    Pietta PG, Gardana C, Mauri PL. Identification of Ginkgo flavonol metabolites after oral administration to humans. J Chromatogr Biomed Sci Appl 1997;693:249–255.CrossRefGoogle Scholar
  54. 54.
    Gilbert GJ. Ginkgo biloba [letter]. Neurology 1997;48:1137.PubMedGoogle Scholar
  55. 55.
    Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion [letter]. Neurology 1996;46:1775–1776.PubMedGoogle Scholar
  56. 56.
    Vale S. Subarachnoid hemorrhage associated with Ginkgo biloba [letter]. Lancet 1998;352:36.PubMedCrossRefGoogle Scholar
  57. 57.
    Matthews MK. Association of Ginkgo biloba with intracranial hemorrhage [letter]. Neurology 1998;50:1933–1934.PubMedGoogle Scholar
  58. 58.
    Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997;336:1108.PubMedCrossRefGoogle Scholar
  59. 59.
    Yagmur E, Piatkowski A, Groger A, Pallua N, Gressner AM, Kiefer P. Bleeding complication under Gingko biloba medication. Letter to the Editor. Am J Hematol 2005;79:343–345.PubMedCrossRefGoogle Scholar
  60. 60.
    Bebbington A, Kulkarni R, Roberts P. Ginkgo biloba. Persistent bleeding after total hip arthroplasty caused by herbal self-medication. J Arthroplasty 2005;20(l): 125–126.PubMedGoogle Scholar
  61. 61.
    Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4-O-mehtylpyridoxine in Ginkgo biloba leaves, Ginkgo medications, and Japanese ginkgo food. Planta Med 1996;62:548–551.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Timothy S. Tracy

There are no affiliations available

Personalised recommendations